Private equity firm Parabellum Investments has acquired Advanco, a tracking system for serialised pharmaceutical products. Advanco’s Serialization Software allows manufacturers to track the serial numbers of every medicine, helping to protect revenues and safeguard health authorities and patients from counterfeits.
Advanco is based in Brussels, Belgium, and supplies global pharmaceuticals including Pfizer, Zentiva, UCB and Helsinn, and its software is currently used in over 35 countries worldwide. With the acquisition, Advanco plans ambitious international growth, initially focusing on the US, Russia and Europe.
Alf Goebel, CEO of Advanco, said: “The race is on to find new drugs to combat COVID-19, so there has never been a more important time for Advanco. Pharmaceutical serialisation is critical to help leaders in international healthcare combat the market for counterfeit and stolen medicines which now looks set to rocket.”
Rami Cassis, CEO of Parabellum Investments, added: “In the near future, almost every product is likely to be serialised. This gives peace of mind of knowing exactly how and where a product was made and, by authenticating sources of raw materials and the manufacturing process, has ethical and environmental applications. Advanco has a proven, resilient and scalable technology on which we plan to build with acquisitions in the coming years.”
